SCHEMBL5735308

SCHEMBL5735308

O=C(O)N1CCCC1COc1cc(OCc2ccccc2)cc2nc[nH]c(=O)c12

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SPHK2 Q9NRA0 5/20 0.43
IP6K1 Q92551 1/20 0.43
CHRNB2 P17787 2/20 0.40
CHRNA7 P36544 2/20 0.40
CHRNA4 P43681 2/20 0.40
CHRNA5 P30532 1/20 0.40
KCNH2 Q12809 2/20 0.39
MCHR1 Q99705 2/20 0.39
SPHK1 Q9NYA1 5/20 0.39
MET P08581 1/20 0.39
ABHD6 Q9BV23 1/20 0.37
DAGLA Q9Y4D2 1/20 0.37
CPT1A P50416 1/20 0.37
CPT1B Q92523 1/20 0.37
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520472 1.00 SPHK2 (0.43) SPHK2IP6K1CHRNB2CHRNA7CHRNA4
SCHEMBL4924585 0.87 ALDH1A1 (0.36) CPT1ACPT1BCHRNB4CHRNA3
SCHEMBL3428136 0.86 F2RL3 (0.38) CHRNB4CHRNA3
SCHEMBL2797321 0.85 CPT1A (0.36) ABHD6DAGLACPT1ACPT1B
SCHEMBL2799815 0.84 DAGLB (0.39) CPT1ACPT1B
SCHEMBL3523231 0.83 SPHK2 (0.44) SPHK2CHRNB2CHRNA7CHRNA4CHRNA5
SCHEMBL3275718 0.80 IP6K1 (0.61) IP6K1
SCHEMBL29717416 0.80 IP6K1 (0.61) IP6K1
SCHEMBL4618217 0.79 FAAH (0.45) SPHK2SPHK1
SCHEMBL3429735 0.78 CHRNB2 (0.38) SPHK2CHRNB2CHRNA7CHRNA4CHRNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622620-A1 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AstraZeneca AB (SE) 2006-02-08 EP disclosed
WO-2004096226-A1 QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2004-11-11 WO disclosed